基本信息
浏览量:454
职业迁徙
个人简介
My laboratory group’s research efforts are focused on three areas, the first of which is identifying new genes and pathways that contribute to cancer pathogenesis in general, and the pathobiology of multiple myeloma and non-Hodgkin lymphoma in particular. For example, we have recently identified the zinc finger transcription factor ZKSCAN3, and the tight junction protein TJP1, as novel mediators of myeloma and lymphoma proliferation and drug resistance, respectively. A second area is in validating novel therapeutic targets using approaches that could be translated to the clinic for patients with relapsed and/or refractory hematologic malignancies, and we have especially been interested in targeting protein homeostasis and the
ubiquitin-proteasome pathway in this regard. Our notable successes have included validation of proteasome inhibitors such as bortezomib and carfilzomib in models of hematologic malignancies, and of combination regimens based on these agents. Current research is looking at approaches that may target upstream mechanisms such as heat shock and chaperone proteins, and E3 ubiquitin ligases. Finally, we also are interested in understanding the mechanisms responsible for resistance to novel therapeutic approaches to further improve their efficacy, and develop biomarkers for use in personalizing cancer therapy. As part of the latter effort, we have developed and characterized models of drug-resistance to several novel agents, including bortezomib and carfilzomib, as well as lenalidomide and pomalidomide. Also, our group’s past efforts have included drug screening projects that have isolated novel immunoproteasome and E3 ligase inhibitors, and a current project is utilizing functional genomic approaches to identify synthetic lethal genes that can be targeted in high-risk molecular subtypes of hematologic malignancies. These efforts have allowed us to take drugs from the pre-clinical arena through to their ultimate regulatory approval, and also complete novel gene discovery efforts that have identified new aspects of cancer pathobiology.
研究兴趣
论文共 841 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nature Communicationsno. 1 (2024): 615-615
The New England journal of medicine (2024)
Transplantation and Cellular Therapyno. 2 (2024): S96
Oren Pasvolsky,Curtis Marcoux,Jianliang Dai,Denái R Milton,Mark R Tanner, Naureen Syed, Qaiser Bashir,Samer Srour,Neeraj Saini,Paul Lin,Jeremy Ramdial,Yago Nieto,
Transplantation and cellular therapy (2024)
BLOOD CANCER JOURNALno. 1 (2024)
Transplantation and Cellular Therapyno. 2 (2024): S379-S380
Andrew Spencer, Philippe Moreau,Maria-Victoria Mateos, Hartmut Goldschmidt,Kenshi Suzuki,Mark-David Levin,Pieter Sonneveld,Robert Z. Orlowski,Sung-Soo Yoon,Saad Z. Usmani, Katja Weisel,Donna Reece,
Blood advancesno. 2 (2024): 388-398
Miao Xian,Qiang Wang,Liuling Xiao, Ling Zhong,Wei Xiong,Lingqun Ye, Pan Su, Chuanchao Zhang, Yabo Li,Robert Z Orlowski, Fenghuang Zhan, Siddhartha Ganguly,
Nature communicationsno. 1 (2024): 5767-5767
Portia Smallbone,Supawee Saengboon,Qaiser Bashir, Blessie Elizabeth Nelson,Jeremy Ramdial,Neeraj Y. Saini,Chitra Hosing,Uday R. Popat,Ruby Delgado,Melody Becnel,Hans C. Lee,Robert Orlowski,
Transplantation and Cellular Therapyno. 2 (2024): S388-S389
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn